- Home
- IRON vs NXRT Comparison
IRON vs NXRT Comparison
Compare IRON & NXRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRON
- NXRT
- Stock Information
- Founded
- IRON 2017
- NXRT 2014
- Country
- IRON United States
- NXRT United States
- Employees
- IRON N/A
- NXRT N/A
- Industry
- IRON Biotechnology: Pharmaceutical Preparations
- NXRT Real Estate Investment Trusts
- Sector
- IRON Health Care
- NXRT Real Estate
- Exchange
- IRON Nasdaq
- NXRT Nasdaq
- Market Cap
- IRON 839.3M
- NXRT N/A
- IPO Year
- IRON N/A
- NXRT N/A
- Fundamental
- Price
- IRON $50.35
- NXRT $44.91
- Analyst Decision
- IRON Buy
- NXRT Hold
- Analyst Count
- IRON 8
- NXRT 5
- Target Price
- IRON $64.13
- NXRT $47.25
- AVG Volume (30 Days)
- IRON 146.6K
- NXRT 88.6K
- Earning Date
- IRON 08-08-2024
- NXRT 10-29-2024
- Dividend Yield
- IRON N/A
- NXRT 4.12%
- EPS Growth
- IRON N/A
- NXRT N/A
- EPS
- IRON N/A
- NXRT 3.35
- Revenue
- IRON N/A
- NXRT $270,841,000.00
- Revenue This Year
- IRON N/A
- NXRT N/A
- Revenue Next Year
- IRON N/A
- NXRT $1.63
- P/E Ratio
- IRON N/A
- NXRT $13.69
- Revenue Growth
- IRON N/A
- NXRT N/A
- 52 Week Low
- IRON $25.60
- NXRT $26.21
- 52 Week High
- IRON $77.60
- NXRT $48.37
- Technical
- Relative Strength Index (RSI)
- IRON 61.60
- NXRT 50.83
- Support Level
- IRON $48.69
- NXRT $45.58
- Resistance Level
- IRON $51.11
- NXRT $48.37
- Average True Range (ATR)
- IRON 2.23
- NXRT 0.96
- MACD
- IRON 0.02
- NXRT -0.19
- Stochastic Oscillator
- IRON 60.91
- NXRT 20.82
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company that is dedicated to transforming the lives of patients with hematologic disorders. The company is building a portfolio of inventive therapeutic candidates that affect fundamental pathways of red blood cell biology. Disc Medicine is committed to developing treatments that empower and bring hope to the many patients who suffer from hematologic disease. The Company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis.